The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 11,988.00
Bid: 12,016.00
Ask: 12,020.00
Change: -38.00 (-0.32%)
Spread: 4.00 (0.033%)
Open: 12,070.00
High: 12,144.00
Low: 11,882.00
Prev. Close: 12,026.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

GLOBAL MARKETS-World shares rise on recovery hopes after record November

Tue, 01st Dec 2020 13:47

(Adds details, updates prices, changes dateline)

* World shares up 0.4%, U.S. futures up sharply

* Vaccine hopes drives optimism after EZ factory recovery
falters

* China factory activity growth hits decade high in November

* U.S. dollar weakens, Bitcoin off record highs

* Oil volatile after OPEC+ talks delay, copper up

By Danilo Masoni

MILAN, Dec 1 (Reuters) - World shares rose to just below
record peaks on Tuesday after factory surveys boosted
expectations of a recovery from the COVID-19 downturn, with
drugmakers seeking fast approval for vaccines and authorities
looking set to maintain stimulus.

Bets on more easing from the U.S. Federal Reserve to help
the pandemic-hit economy through the winter weighed on the
dollar as riskier currencies rose, while crude prices struggled
to join the bounce after oil-producing countries delayed a
decision on output cuts.

The MSCI world equity index, which tracks
shares in 49 countries, was up 0.4% by 1323 GMT.

Breakthroughs in vaccine developments from top drugmakers
Pfizer, Moderna and AstraZeneca in
November along with a market-friendly outcome of the U.S.
presidential election helped the index score its best month on
record, up 12% to new all-time peaks.

"We believe the rally can continue, with the current
pipeline of expected vaccine rollouts in line with our central
scenario of widespread availability in the second quarter of
2021," said Mark Haefele, Chief Investment Officer at UBS Global
Wealth Management in Zurich.

"We also believe that a divided U.S. government - which
looks the most likely outcome - is no impediment to a rising
market," he added.

In Europe the pan-regional STOXX 600 benchmark was
up 0.7%, while U.S. stock index futures also pointed to a strong
start on Wall Street, with investors focusing on November
manufacturing surveys from Europe and the United States.

Euro zone factory surveys were less upbeat than China's as
growth in the region cooled last month from a 32-month high on
renewed lockdown measures. However, optimism did improve amid
progress in developing COVID-19 vaccines.

In the UK, factories recorded their fastest growth in almost
three years last month.

Earlier the MSCI's broadest index of Asia-Pacific shares
outside Japan closed up 1.3%. China's blue-chip
CSI300 index rose 2.2% after a business survey showed
activity in China's factory sector accelerated at the fastest
pace in a decade in November.

Japan's Nikkei closed near a 29-1/2-year high.

"What we are seeing today is that upward trend reasserting
itself, given the positive news on the vaccine front, China's
growth picking up, and the tremendous faith in the ability of
central banks to keep the markets afloat," said Stephen Miller,
market strategist for GSFM Funds Management.

Pfizer on Tuesday said it had asked for EU emergency
authorization of its vaccine, taking it closer to launch
following a similar move in the United States last month.

Moderna applied for U.S. authorization on Monday
after full results from a late-stage study showed it was 94.1%
effective with no serious safety concerns.

In foreign exchange markets, the dollar was under pressure
after closing out on Monday its worst month since July with a
little bounce, and as investors reckon on even more U.S.
monetary easing.

The dollar index was last down 0.2% to 91.758.

In a speech released late on Monday, Fed chair Jerome Powell
said a slowing recovery and a surging pandemic meant the U.S.
was entering a "challenging" few months, with the potential
deployment of a vaccine still facing hurdles.

The Fed holds its next policy meeting later this month.

That lifted the euro close to a three-month high,
up 0.4% at $1.1974, while risk-related currencies such as the
Canadian and Aussie dollar rose against the greenback.

Elsewhere sterling was up 0.5% after hitting a
three-month high as traders clung to hopes for a Brexit trade
deal before the year's end, despite the lack of tangible
progress.

Bitcoin was volatile, last down 6% after hitting
a record high earlier in the day.

Bond markets were quieter. Germany's 10-year bond yield
nudged off three-week lows at -0.564%, while
southern European debt yields also edged up, though they held
close to record lows ahead of next week's European Central Bank
meeting.

Data on Tuesday showing a bigger than expected drop in euro
zone inflation in November didn't move bond markets much but
cemented expectations for the ECB to take action.

"The message is clear for the ECB. As this has been the base
case for some time now, it will without a doubt make the ECB
loosen policy once again," said ING senior economist Bert Colijn
in Amsterdam.

U.S. 10-year yields were up slightly at 0.8602%
as the U.S. Congress began a two-week sprint to secure funding
and avoid a possible shutdown amid the coronavirus pandemic.

Metal markets were buoyant, reflecting the risk-on mood.
London copper prices pushed back towards Monday's 7-1/2-year
high, helped by the robust data from China.

Oil prices were volatile after leading producers delayed
talks on 2021 output policy, while the coronavirus pandemic
continued to sap fuel demand.

OPEC+ delayed talks on output policy for next year until
Thursday, sources told Reuters, as key players still disagreed
on how much oil they should pump amid weak demand.

Brent crude futures were last 0.2% lower at $47.8 a
barrel, while U.S. crude also eased 0.4% to $45.16.

(Reporting by Danilo Masoni in Milan, additional reporting by
Paulina Duran in Sydney; Editing by Mike Collett-White and Jan
Harvey)

More News
16 Jan 2024 17:17

FTSE 100 hits one-month low, precious miners biggest drag

FTSE 100 down 0.5%, FTSE 250 flat

*

Read more
16 Jan 2024 16:17

London close: Stocks finish lower as wage growth eases

(Sharecast News) - London's stock markets finished in the red on Tuesday, as investors assessed the latest UK jobs data.

Read more
16 Jan 2024 11:58

LONDON MARKET MIDDAY: FTSE 100 falls despite cooler UK wage growth

(Alliance News) - The FTSE 100 in London was down at midday Tuesday, as investors nervously eye Wednesday's UK inflation data and what it will mean for interest rates.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
9 Jan 2024 10:50

Novartis in advanced talks to buy Cytokinetics- source

Jan 9 (Reuters) - Swiss drugmaker Novartis is in the lead to acquire Cytokinetics in a deal that could value the drug developer at well over $10 billion, a source familiar with the matter said on Monday.

Read more
8 Jan 2024 14:08

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
6 Jan 2024 17:44

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
5 Jan 2024 12:00

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
3 Jan 2024 17:48

London close: Stocks fall amid rising geopolitical concerns

(Sharecast News) - London stocks closed lower on Wednesday - the 40th anniversary of the FTSE 100's launch - as sentiment remained cautious due to increasing tensions in the Middle East.

Read more
3 Jan 2024 16:52

LONDON MARKET CLOSE: Stocks down ahead of US Fed minutes

(Alliance News) - Stock prices in London closed lower on Wednesday, as investors nervously look ahead to the latest US Federal Reserve meeting minutes.

Read more
3 Jan 2024 11:07

Jefferies upgrades GSK to 'buy', cuts AstraZeneca to 'hold'

(Sharecast News) - Jefferies has upgraded its rating on GlaxoSmithKline to 'buy' and cut AstraZeneca to 'hold' as part of its review of the European pharma sector.

Read more
3 Jan 2024 10:16

IN BRIEF: Nuformix narrows annual loss as develops drug assets

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Pretax loss narrows to GBP927,972 in 18 months that ended September 30 from GBP1.3 million in the 12 months that ended March 31, 2022, following its change of financial year-end. Has no meaningful revenue in either period, so reduced loss is due to lower administrative expenses.

Read more
3 Jan 2024 10:12

AIM WINNERS & LOSERS: C4X gets Astra payment; Getech wins eight deals

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
3 Jan 2024 09:23

LONDON BROKER RATINGS: GSK raised to 'buy'; AstraZeneca cut to 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.